Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies

Condition(s) studied

Investigational drug(s) / intervention(s)

Desmopressin (DDAVP): Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure

Sodium Chloride: Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure

Study summary

The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding.

Researchers will compare desmopressin (DDAVP) to placebo to see if the drug reduces the risk of bleeding events related to kidney biopsy.

Participants will receive intravenous desmopressin medication (100ml) or placebo (100mL of saline solution) before the kidney biopsy.

Eligibility

Primary outcome measure(s)

• Bleeding events — Immediately post-biopsy until 48 hours post-biopsy
  Incidence of bleeding related to the procedure

Trial sites (1)

More Hospital de Clinicas de Porto Alegre trials in Brazil

Other trials for the same condition